These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 648557)

  • 21. DNA-binding parameters of daunorubicin and doxorubicin in the conditions used for studying the interaction of anthracycline-DNA complexes with cells in vitro.
    Schneider YJ; Baurain R; Zenebergh A; Trouet A
    Cancer Chemother Pharmacol; 1979; 2(1):7-10. PubMed ID: 498422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alteration of chromatin structure induced by the binding of adriamycin, daunorubicin and ethidium bromide.
    Grimmond HE; Beerman T
    Biochem Pharmacol; 1982 Nov; 31(21):3379-86. PubMed ID: 7150361
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative uptake of adriamycin and daunorubicin in sensitive and resistant friend leukemia cells measured by flow cytometry.
    Tapiero H; Fourcade A; Vaigot P; Farhi JJ
    Cytometry; 1982 Mar; 2(5):298-302. PubMed ID: 6951693
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enzymatic activation and binding of adriamycin to nuclear DNA.
    Sinha BK; Trush MA; Kennedy KA; Mimnaugh EG
    Cancer Res; 1984 Jul; 44(7):2892-6. PubMed ID: 6327028
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biodistribution of intravenously injected [14C] doxorubicin and [14C] daunorubicin in mice: concise communication.
    Harrison K; Wagner NH
    J Nucl Med; 1978 Jan; 19(1):84-6. PubMed ID: 621570
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The interaction of daunorubicin and doxorubicin with DNA and chromatin.
    Zunino F; Di Marco A; Zaccara A; Gambetta RA
    Biochim Biophys Acta; 1980 Apr; 607(2):206-14. PubMed ID: 7370266
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intracellular uptake of 7-con-o-methylnogarol and adriamycin by cells in culture and its relationship to cell survival.
    Bhuyan BK; McGovren JP; Crampton SL
    Cancer Res; 1981 Mar; 41(3):882-7. PubMed ID: 6450639
    [No Abstract]   [Full Text] [Related]  

  • 28. Comparison of the liver subcellular distribution of free daunomycin and that bound to galactosamine targeted N-(2-hydroxypropyl)methacrylamide copolymers, following intravenous administration in the rat.
    Wedge SR; Duncan R; Kopeckova P
    Br J Cancer; 1991 Apr; 63(4):546-9. PubMed ID: 1827030
    [No Abstract]   [Full Text] [Related]  

  • 29. Letter: Digoxin does not prevent daunorubicin or adriamycin from binding to rat heart muscle.
    Smith BJ; Kundv D
    Br J Cancer; 1976 Feb; 33(2):232-3. PubMed ID: 1259917
    [No Abstract]   [Full Text] [Related]  

  • 30. Accumulation of degradation products of doxorubicin and pirarubicin formed in cell culture medium within sensitive and resistant cells.
    Fiallo M; Laigle A; Borrel MN; Garnier-Suillerot A
    Biochem Pharmacol; 1993 Feb; 45(3):659-65. PubMed ID: 8095138
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interaction of new derivatives of daunorubicin and adriamycin with DNA.
    Arlandini E; Vigevani A; Arcamone F
    Farmaco Sci; 1977 May; 32(5):315-23. PubMed ID: 862886
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Subcellular distribution of daunorubicin in the P-glycoprotein-mediated multidrug-resistant cell line K562/ADR].
    Gong Y; Wang Y; Chen F
    Zhonghua Zhong Liu Za Zhi; 2001 May; 23(3):184-6. PubMed ID: 11783080
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differences in uptake of adriamycin and daunomycin by normal BM cells and acute leukemia cell determined by flow cytometry.
    Sonneveld P; van den Engh GJ
    Leuk Res; 1981; 5(3):251-7. PubMed ID: 7266019
    [No Abstract]   [Full Text] [Related]  

  • 34. A differential interaction of daunomycin, adriamycin, and N-trifluoroacetyladriamycin 14-valerate with mouse peritoneal macrophages.
    Facchinetti T; Raz A; Goldman R
    Cancer Res; 1978 Nov; 38(11 Pt 1):3944-9. PubMed ID: 212183
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of the subcellular localization of daunorubicin in multidrug-resistant K562 cell line.
    Gong Y; Wang Y; Chen F; Han J; Miao J; Shao N; Fang Z; Ou Yang R
    Leuk Res; 2000 Sep; 24(9):769-74. PubMed ID: 10978781
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adriamycin and daunorubicin disposition in the rabbit.
    Bachur NR; Hildebrand RC; Jaenke RS
    J Pharmacol Exp Ther; 1974 Nov; 191(2):331-40. PubMed ID: 4417723
    [No Abstract]   [Full Text] [Related]  

  • 37. Some determinants of the therapeutic efficacy of actinomycin D (NSC-3053), adriamycin (NSC-123127), and daunorubicin (NSC-83142).
    Schwartz HS
    Cancer Chemother Rep; 1974; 58(1):55-62. PubMed ID: 4521481
    [No Abstract]   [Full Text] [Related]  

  • 38. Uptake of adriamycin and daunomycin in L1210 and human leukemia cells: a comparative study.
    Chervinsky DS; Wang JJ
    J Med; 1976; 7(1):63-79. PubMed ID: 1064679
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distribution of daunomycin and adriamycin in mice. A comparative study.
    Rosso R; Esposito M; Sala R; Santi L
    Biomedicine; 1973 Jul; 19(7):304-7. PubMed ID: 4593553
    [No Abstract]   [Full Text] [Related]  

  • 40. Uptake of free and DNA-bound daunorubicin and doxorubicin into human leukemic cells.
    Paul C; Peterson C; Gahrton G; Lockner D
    Cancer Chemother Pharmacol; 1979; 2(1):49-52. PubMed ID: 498420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.